![Biotech Stocks Facing FDA Decision In December 2022]( "fda-oct24.jpg")
Now, let’s take a look at the biotech stocks facing FDA decision in December.
![Biotech Stocks Facing FDA Decision In November 2022]( "fda-oct26.jpg")
The FDA has approved 28 novel drugs so far this year, including 2 in October
![Biotech Stocks Facing FDA Decision In October 2022]( "fda-may25.jpg")
The FDA has approved only 24 novel drugs this year (Jan. to Sep.) compared to 40 during the same period last year.
![Biotech Stocks Facing FDA Decision In September]( "fda-aug26.jpg")
The month of August witnessed the FDA approving the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions on Aug.17. This one-time gene therapy by the name Zynteglo, developed by bluebird bio Inc. (BLUE), reportedly carries a price tag of $2.8 million.